Britain and America have announced a important commercial pact that will preserve no duties on UK medicine shipments entering the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has committed to increase expenditure on medicines through the National Health Service (NHS). This pledge secures that duties on these crucial goods will be held at zero for a duration of the next three years.
This agreement comes after previous warnings to dramatically increase import taxes on patented pharmaceutical imports, with increases discussed as high as double the cost.
"This arrangement with the United Kingdom reinforces the global environment for new treatments and brings long-overdue equity to American-British medicine commerce," a statement declared.
Commercial Importance
Drugs constitute one of the the United Kingdom's largest goods shipped to the US, which is by far the largest destination for large companies like GSK and AstraZeneca.
Export figures reveal that in the one-year period leading up to September, the UK exported medicines totaling billions to the US. This figure represented 17.4% of British export trade in that timeframe.
"This deal protects work, increases investment and sets the stage for the UK to become a worldwide center for life sciences," a minister remarked.
Specific NHS Changes
The agreement involves several notable pledges from the British government:
- Revised Affordability Limit: The UK will raise the price threshold at which it deems new medicines to be unaffordable by a quarter.
- Higher Drug Budget: There is a goal to increase total health service expenditure on drugs from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The sum pharmaceutical firms must return to the NHS to control costs will be restricted at fifteen percent. In the past, rebates exceeded 20%.
Broader Context
The deal follows a ongoing tension between the pharmaceutical industry and the UK government over spending levels and regulatory access.
These tensions were intensified by claims that American patients were paying significantly more for the same drugs than people in the UK and Europe.
Over the last 18 months, several significant drug company projects in the UK have been halted or abandoned, while multi-billion-dollar expansions have been announced toward projects in the United States.
One official acknowledged that the NHS needed to invest a greater share on treatments, noting that its expenditure on drugs had declined as a percentage of its resources over the past decade.
